Clinical Trials
66 trialsHOPE-07-MIBC
West China Hospital
Metronomic Oral Paclitaxel Monotherapy and Combined Immunotherapy for Advanced HER2-Negative Breast Cancer: A Two-Stage Dose Exploration and Expansion Trial
Zhejiang Cancer Hospital
A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung CancerInhibitors or Platinum-Based Agents for Small Cell Lung Cancer.
Hangzhou DAC Biotechnology Co., Ltd.
Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases
Icahn School of Medicine at Mount Sinai
Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma
Sun Yat-sen University
A Clinical Study for the Safety and Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
Shanghai Best-Link Bioscience, LLC
GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.
Sun Yat-sen University
Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unresectable Stage III NSCLC
Hunan Province Tumor Hospital
IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors
Nanjing Immunophage Biotech Co., Ltd
Fasting-Mimicking Diet Combined With IO-TKI Combination Therapy in Patients With Metastatic Renal Cell Carcinoma
Qilu Hospital of Shandong University
Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients
Shanghai Pulmonary Hospital, Shanghai, China
Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.
Sun Yat-sen University
Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer
Sun Yat-sen University
Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant Chemotherapy
Tianjin Medical University Cancer Institute and Hospital
A Phase III Clinical Study of WX390 Combined With Toripalimab Versus Investigator's Choice of Therapy in Patients With Recurrent or Metastatic Cervical Cancer Who Have Failed Prior Platinum-Based Treatment
Shanghai Jiatan Pharmatech Co., Ltd
TD-NEOE3V3
Tang-Du Hospital
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
China Medical University, China
SHINE
Sun Yat-sen University
A Phase II Study of Utidelone With Toripalimab in Advanced Cervical Cancer
Zhongnan Hospital
Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
A Prospective, Multicenter, Open-label, Single-arm Phase II Clinical Study Evaluating the Efficacy and Safety of Spatially Fractionated Radiotherapy Combined With the PraG Strategy for the Treatment of Soft Tissue Sarcoma
First Affiliated Hospital of Guangxi Medical University
A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
China Medical University, China
A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer
Tongji Hospital
Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial
Jiangsu Cancer Institute & Hospital
A Phase II Study of Toripalimab Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refractory Esophageal Squamous Cell Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Toripalimab Combined With Anthracycline-free or Anthracycline-containing Chemotherapy as Neoadjuvant Chemotherapy for Early Triple Negative Breast Cancer
Henan Cancer Hospital
Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC
Tianjin Medical University Cancer Institute and Hospital
Safety and Tolerability of a mRNA Vaccine Encoding Tumor-Specific Circular RNA Antigens in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter Study
Tianjin Medical University Cancer Institute and Hospital
Vedisertib (RC48/ADC) Combined With Toripalimab in Bladder-preserving Treatment
Qilu Hospital of Shandong University
OHAI-NMIBC-01
First Affiliated Hospital of Wenzhou Medical University
A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer
Peking Union Medical College Hospital
Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma
Affiliated Hospital of Guangdong Medical University
ONTOP
Shanghai Pudong Hospital
PUPA
Sun Yat-sen University
A Randomized Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy for Stage II-III Triple-negative Breast Cancer (TNBC).
Shengjing Hospital
Adjuvant
Shanghai Pulmonary Hospital, Shanghai, China
Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma
Sichuan University
TC as Adjuvant Therapy After Surgery for Locally Recurrent Resectable Nasopharyngeal Carcinoma: a Single-arm Clinical Trial
Sun Yat-sen University
Chemoimmunotherapy With or Without SBRT Before Surgery for Locally Advanced Oral and Oropharyngeal Cancer
Sun Yat-sen University
A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours
LaNova Medicines Limited
TRACER
Sixth Affiliated Hospital, Sun Yat-sen University
MOTION-NSCLC
Guangdong Association of Clinical Trials
SPRING
Peking University Shenzhen Hospital
Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT)
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors
Coherus Oncology, Inc.
BTLA Inhibitor (JS004) Combined with Toripalimab and Chemotherapy in the Perioperative Treatment of Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
Henan Provincial People's Hospital